+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cardiovascular Drugs Market Research Reports

Beta-2 Receptors Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Beta-2 Receptors Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Glycan Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Glycan Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Aldosterone Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Aldosterone Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Angiotensin Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Angiotensin Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Hypoxia Inducible Factor 1 (HIF-1) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Hypoxia Inducible Factor 1 (HIF-1) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Endothelin Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Endothelin Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Apolipoprotein B (ApoB) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Apolipoprotein B (ApoB) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Vascular Endothelial Growth Factor A Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Vascular Endothelial Growth Factor A Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Angiotensin Converting Enzyme (ACE) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Angiotensin Converting Enzyme (ACE) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chronic Heart Failure- Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Heart Failure- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Intracranial Arterial Diseases - Pipeline Insight, 2025 - Product Thumbnail Image

Intracranial Arterial Diseases - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Recurrent Pericarditis - Pipeline Insight, 2025 - Product Thumbnail Image

Recurrent Pericarditis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Cardiotoxicity - Pipeline Insight, 2025 - Product Thumbnail Image

Cardiotoxicity - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Aneurysmal Subarachnoid Hemorrhage- Pipeline Insight, 2025 - Product Thumbnail Image

Aneurysmal Subarachnoid Hemorrhage- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Angioedema- Pipeline Insight, 2025 - Product Thumbnail Image

Angioedema- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Loading Indicator

The Cardiovascular Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cardiovascular diseases. These drugs are used to treat conditions such as hypertension, coronary artery disease, congestive heart failure, and arrhythmias. Cardiovascular drugs are also used to reduce the risk of stroke, heart attack, and other cardiovascular events. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. Major players in the market include Pfizer, Merck, Novartis, Sanofi, and Bristol-Myers Squibb. These companies are involved in the research, development, and production of cardiovascular drugs. Additionally, there are a number of smaller companies that specialize in the production of generic cardiovascular drugs. These companies include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more